Fluidigm-Singapore completes final milestone toward full manufacturing operations
Off-shore fab positions Fluidigm to move rapidly into the real-time qPCR market
Fluidigm Corporation has announced that its Singapore-based manufacturing facility has ramped up to full process R&D and manufacturing operations, less than a year after opening its doors. The rapid startup boosts the Company's entry into the billion dollar real-time qPCR market, enabling production of BioMark(TM) dynamic arrays to supply high-end users. According to the company, these unique biochips increase qPCR efficiency by orders of magnitude and may replace microwell plates as the industry standard of the future.
"We view our Singapore operation as critical to our long-term success," said Fluidigm CEO Gajus Worthington. "This group has proven its mettle with production of our first product, TOPAZ® screening chips. Now, we are poised for high-volume, low-cost manufacturing to meet the demand in a much larger market." Manufacturing engineers at corporate headquarters in South San Francisco collaborated with the Singapore team to bring the facility up to speed. The off-shore strategy takes advantage of Singapore's high-quality talent, which is a legacy of its semiconductor industry.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Eppendorf grows faster than the market
Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease
ZEISS: High-Tech Drives Growth - Medical technology and industrial metrology business still on track for growth

Innophore GmbH - Graz, Austria
OctoPlus appoints Jan Hendrik Egberts as CEO

Microscaffolds – a New Strategy in Tissue Engineering - Living cells meet high-resolution 3D printing process

Merck Appoints New Executive Board Members - Bernd Reckmann to retire

Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.
AlgoNomics appoints Philippe Stas as CEO - Founder Dr. Ignace Lasters remains CSO and director of the company
